psoriasis vulgaris
Conditions
Interventions
PSORI-CM02 granule group:PSORI-CM02 granule + Yinxieling tablet placebo
Yinxieling tablet group:Yinxieling tablets + PSORI-CM02 granule placebo
placebo group:Yinxieling tablet placebo + PSORI-CM02 granule placebo
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Patients with stable plaque psoriasis with syndrome pattern of blood stasis more than one year; 2.male or female patient between 18 to 65 years old; 3.PASI between 3 to 10, meanwhile BSA <= 10%; 4.Informed consent.
Exclusion criteria
Exclusion criteria: 1. Skin lesions manifest as droplets, or psoriatic lesions can only be seen on face, scalp, nails, balanus, mucus and palmarplantar areas; 2. Acute progressive psoriasis, and erythroderma tendency; 3. Pregnant, lactating, or those who plan to become pregnant in a year; 4. SAS more than 50 or SDS more than 53, or with other psychiatric disorders; 5. With history of primary cardiovascular, respiratory, digestive, urinary, endocrinologic and hematologic diseases, which can't be controlled through ordinary treatments. Those who with malignant diseases, infections, electrolyte imbalance, acid-base disturbance. Patients with clinical test results listed below: AST or ALT 3 times more than normal upper limit; Creatinine 1.5 times more than normal upper limit; Hemoglobin elevates 20g/L more than normal upper limit; Platelet count less than 75.0 x 10^9/L; White blood cell less than 3.0 x 10^9/L; Or any other abnormal laboratory test results, assessed by investigators, that are not suitable for this clinical study; 6. Allergic to any medicine or ingredients used in this study; 7. Participating other clinical trials or participated within 1 month; 8. Topical treatments with corticosteroids or Retinoic acid within 2 weeks; systemic therapy or phototherapy (UVB and PUVA) within 4 weeks; biological therapy within 12 weeks; 9. Patients need systemic treatment with western medicine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement rate of PASI;time to relapse;rebound rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Psoriasis Area Severity Index;visual analogue scale;Body Surface Area;Dermatology Quality Life Index;Relapsing rate of treatment peroid and follow-up period;time of efficacy onset; | — |
Countries
China
Contacts
Public ContactLu Chuanjian
Outcome results
None listed